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Introduction: Despite significant progress, a disease-modifying therapy for Alzheimer’s disease (AD) has not yet been
developed. Recent findings implicate soluble oligomeric amyloid beta as the most relevant protein conformation in AD
pathogenesis. We recently described a signaling cascade whereby oligomeric amyloid beta binds to cellular prion
protein on the neuronal cell surface, activating intracellular Fyn kinase to mediate synaptotoxicity. Fyn kinase has
been implicated in AD pathophysiology both in in vitro models and in human subjects, and is a promising new
therapeutic target for AD. Herein, we present a Phase Ib trial of the repurposed investigational drug AZD0530, a
Src family kinase inhibitor specific for Fyn and Src kinase, for the treatment of patients with mild-to-moderate AD.
Methods: The study was a 4-week Phase Ib multiple ascending dose, randomized, double-blind, placebo-controlled
trial of AZD0530 in AD patients with Mini-Mental State Examination (MMSE) scores ranging from 16 to 26. A total of 24
subjects were recruited in three sequential groups, with each randomized to receive oral AZD0530 at doses of 50 mg,
100 mg, 125 mg, or placebo daily for 4 weeks. The drug:placebo ratio was 3:1. Primary endpoints were safety,
tolerability, and cerebrospinal fluid (CSF) penetration of AZD0530. Secondary endpoints included changes in
clinical efficacy measures (Alzheimer’s Disease Assessment Scale – cognitive subscale, MMSE, Alzheimer’s Disease
Cooperative Study – Activities of Daily Living Inventory, Neuropsychiatric Inventory, and Clinical Dementia Rating
Scale – Sum of Boxes) and regional cerebral glucose metabolism measured by fluorodeoxyglucose positron
emission tomography.
Results: AZD0530 was generally safe and well tolerated across doses. One subject receiving 125 mg of AZD0530 was
discontinued from the study due to the development of congestive heart failure and atypical pneumonia, which were
considered possibly related to the study drug. Plasma/CSF ratio of AZD0530 was 0.4. The 100 mg and 125 mg doses
achieved CSF drug levels corresponding to brain levels that rescued memory deficits in transgenic mouse models.
One-month treatment with AZD0530 had no significant effect on clinical efficacy measures or regional cerebral glucose
metabolism.
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Conclusions: AZD0530 is reasonably safe and well tolerated in patients with mild-to-moderate AD, achieving
substantial central nervous system penetration with oral dosing at 100–125 mg. Targeting Fyn kinase may be a
promising therapeutic approach in AD, and a larger Phase IIa clinical trial of AZD0530 for the treatment of patients with
AD has recently launched.
Trial registration: ClinicalTrials.gov: NCT01864655. Registered 12 June 2014.Introduction
Despite considerable ongoing efforts to halt or reverse
the symptoms of Alzheimer’s disease (AD), a disease-
modifying intervention for this devastating illness has
not yet emerged. The major approach to AD therapeutic
development has been to target amyloid-beta (Aβ), by
either limiting its cleavage from the amyloid precursor
protein, or facilitating its clearance by active or passive
immunization [1]. An alternative approach to AD treat-
ment is to target the downstream effects of pathologic Aβ
signaling, without altering protein levels. This may be a
particularly attractive approach as some forms of Aβ could
have important physiologic roles [2,3]. More recently, pre-
clinical focus has changed from insoluble assemblies of
Aβ to oligomeric species (Aβo) and, while the precise na-
ture of the toxic Aβo is not fully understood, a unifying
theme among various preparations and sources is synap-
totoxicity [4-6]. Blocking this detrimental downstream
effect of Aβo may be a key feature of future Aβ-based
therapeutics in AD.
The mechanism by which Aβo causes synaptoxicity is
of significant interest, with a leading hypothesis postulat-
ing the existence of a distinct cell surface receptor medi-
ating its effects. To identify such a potential binding site
of Aβo on neurons, we performed a genome-wide unbiased
screen for cell surface proteins binding Aβo, identifying cel-
lular prion protein (PrPC) as a high-affinity receptor [5].
Aβ binding to PrPC is highly conformation-dependent, and
only Aβo will interact with PrP
C, with no binding detected
in the presence of fibrillary or monomeric Aβ peptide
[5,7-9]. Emphasizing its potential importance, PrPC is re-
quired for most deficits seen in amyloid precursor protein/
presenilin 1 transgenic mice, including spatial learning and
memory deficits, reduced survival, epileptiform discharges,
synapse loss, serotonin fiber degeneration and for cell
death in vitro [10-17]. Human AD brain-derived Aβ
species suppress hippocampal synaptic plasticity in vivo
in a PrPC-dependent fashion, and human AD brain ex-
tracts contain Aβo species that interact with PrP
C as
well as Aβ-PrPC complexes [10,18-20]. Several groups,
including ours, recently showed that the Aβo-PrP
C com-
plex activates an intracellular signaling cascade coupled to
the protein tyrosine kinase Fyn [5,10,21,22]. This is of par-
ticular interest since Fyn has been implicated in AD patho-
genesis across various models, including human subjects[23]. Fyn is central to Aβ signal transduction, and also has
major functional interactions with Tau [24-27], thereby
unifying the two principal pathologies in AD. Thus, block-
ing Fyn kinase may be a promising therapeutic approach in
AD.
Saracatinib (AZD0530) is a small molecule inhibitor of
the Src family kinases, blocking Src, Fyn, Yes and Lyn,
with 2 to 10 nM potency [28]. At 10- to 100-fold higher
concentrations the compound also inhibits Abl family
kinases, without detectable activity in this concentration
range against other kinase families, including c-kit, Csk
and platelet-derived growth factor. Due to its specific in-
hibition of Fyn and Src family kinases, and the fact that
Src family kinases regulate cell proliferation and tumor
cell adhesion, migration and invasion, AZD0530 was ini-
tially developed as a therapy for solid tumors [28]. To
date, more than 500 subjects have received once-daily
oral doses of AZD0530. Preliminary studies indicate that
the dose needed to disrupt the Aβ-PrPC-Fyn signaling
cascade is significantly lower than that needed for cancer
therapy, and doses up to 125 mg daily have been found
to be safe and well tolerated (unpublished data).
Herein we present the results of a 4-week multiple as-
cending dose study of the safety, tolerability, and central
nervous system (CNS) availability of AZD0530 (saracatinib)
in mild-to-moderate AD. We assessed the safety and toler-
ability of three escalating doses of AZD0530, as well as the
ability of the compound to penetrate the CNS, a critical fea-
ture for any AD drug. Secondary aims included changes in




This study protocol was reviewed and approved by the
Yale Human Investigation Committee. All study partici-
pants and their study partners provided written informed
consent to participate in this study. Given the absence of
potential benefit in this short Phase Ib study, participants
were required to provide informed consent for themselves
(that is, surrogate consent was not permitted).
Study population
Men and women aged 50 to 90 years old (inclusive) with
a diagnosis of probable AD dementia based on the
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clinical criteria [29], and Mini-Mental State Examination
(MMSE) [30] score of 16 to 26 were considered for study
participation. Additionally, subjects were required to have
stable permitted medications for 4 weeks prior to study
participation. Cholinesterase inhibitors and memantine
were required to be stable for 12 weeks prior to screen.
Participants also needed to score less than 6 on the
Geriatric Depression Scale [31] and less than or equal
to 4 on the Modified Hachinski Scale [32]. Additionally,
they needed to have completed six grades of education
or have a good work history and speak English fluently.
Amyloid positron emission tomography (PET) imaging
was not used to determine study eligibility.
Participants were excluded from the study if they ex-
hibited any significant neurologic disease other than AD.
Additionally, subjects with a screening magnetic resonance
imaging scan showing evidence of infection, infarction, or
other focal lesions as well as multiple lacunes or lacunes
in a brain region critical for memory were excluded. A
history of schizophrenia or of alcohol or substance abuse/
dependence within the past 2 years (Diagnostic and
Statistical Manual of Mental Disorders, 4th edition criteria)
was also exclusionary. Any subject with a clinically signifi-
cant or unstable medical condition that could have put
the subject at risk due to study participation, or influ-
ence the results, was excluded. Additionally, the following
laboratory results were considered exclusionary: clinically
significant abnormalities in vitamin B12 or thyroid func-
tion tests that might interfere with the study, neutropenia
defined as an absolute neutrophil count of <1,500/μl,
thrombocytopenia defined as platelet count <100 × 103/μl,
current blood clotting or bleeding disorder, or signifi-
cantly abnormal prothrombin time or partial thromboplas-
tin time at screening, or clinically significant abnormalities
in other screening laboratories, including aspartate amino-
transferase >1.5 × upper limit of normal (ULN); alanine
aminotransferase >1.5 × ULN; total bilirubin >1.5 × ULN;
serum creatinine >2.0 × ULN. Additionally, a history of
interstitial lung disease was exclusionary. Residence in
a skilled nursing facility was also considered exclusionary.
Current use (within 30 days of screening) of the follow-
ing medications was exclusionary: typical neuroleptics,
narcotic analgesics, Parkinson’s medications, systemic
corticosteroids, or medications with significant central
anticholinergic activity, or warfarin. Current use (within
30 days of screening and throughout the protocol in-
cluding the 2-week follow-up period) of the following
medications was exclusionary: a) strong CYP3A4 inhib-
itors including: atazanavir, indinavir, ritonavir, saquinavir,
nelfinavir, ketoconazole, itraconazole, clarithromycin,
telithromycin, and nefazodone; b) strong CYP3A4 in-
ducers including: rifampicin, phenytoin, phenobarbital,
and carbamazepine; c) certain CYP3A4 substrates includingcolchicine, cyclosporine, disopyramide, fluticasone, quini-
dine, vinblastine, vincristine. Subjects taking sildenafil, tada-
lafil, and vardenafil were advised to stop taking these
medications for the duration of the trial.
Study design
The study was conducted in the Yale Alzheimer’s Disease
Research Unit between July 2013 and March 2014. This
4-week, multiple ascending dose, randomized, double-
blind, placebo-controlled, Phase Ib trial enrolled 24 subjects.
The subjects were divided into three sequential cohorts.
Each cohort contained six subjects assigned to active drug
and two subjects assigned to placebo. The dose of the first
cohort was 50 mg of oral AZD0530 or placebo per day for 4
to 5 weeks. The dose of the second and third cohorts was to
be determined from the results of cohort 1 and ongoing
preclinical studies, not to exceed 125 mg daily. Each
cohort of eight participants completed the study before
the next cohort was recruited.
The primary aims of this study were to assess the safety
and tolerability of oral AZD0530 in patients with AD and
to determine dose levels that are well tolerated and pro-
vide cerebrospinal fluid (CSF) concentrations predicted
to slow AD progression. Secondary aims were to assess
effects of AZD0530 on clinical efficacy assessments and
brain 18F-fluorodeoxyglucose (FDG) PET changes in a
statistical region of interest (sROI) known to be prefer-
entially affected in AD over longer time periods.
Potential participants who were found to be eligible
based on the initial screening evaluation proceeded to the
baseline assessments. These included safety assessments,
clinical efficacy assessments, 18F-FDG PET imaging, col-
lection of AZD0530 metabolites and AD biomarkers, and
dispensation of study medication. Subjects were seen for
safety visits at weeks 1, 2, and 3. Outcome measures were
collected after 4 weeks on AZD0530 or placebo, including
measures of safety and tolerability, CSF drug concen-
tration, clinical efficacy measures, and 18F-FDG PET
imaging. Study medication could be continued for up
to 5 weeks (35 days) in order to complete all outcome
measures. Study medication compliance was measured
throughout the study. A final safety visit was completed
after the participant had been off AZD0530 or placebo for
approximately 2 weeks.
Safety assessments
Safety assessments included physical and neurological
examinations, MMSE examinations, vital signs (including
blood pressure, pulse, oral temperature, respiration rate,
and weight), electrocardiograms, and clinical laboratories.
Physical and neurological examinations occurred at all
visits except the baseline visit. Electrocardiograms oc-
curred at the screening, and at week 4 and week 6 visits.
Vital signs, clinical laboratories, and MMSE examinations
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AZD0530 has indicated a possible, but rare, relationship
with interstitial lung disease in patients with advanced
solid tumors [33]. For this reason, thoracic high-resolution
computed tomography was obtained if unexplained pul-
monary symptoms arose at any point during the study.
Clinical efficacy measures
At the baseline and week 4 visits, subjects underwent
the following clinical efficacy assessments: Alzheimer’s
Disease Assessment Scale – cognitive subscale (ADAS-cog)
[34], MMSE [30], Alzheimer’s Disease Cooperative Study –
Activities of Daily Living Inventory (ADCS-ADL) [35],
Neuropsychiatric Inventory (NPI) [36], and Clinical
Dementia Rating Scale – Sum of Boxes (CDR-SOB) [37].
The MMSE was also completed at screening and weeks 1,
2, and 3.
18F-FDG PET imaging
Eligible subjects had 18F-FDG PET brain scans performed
at the baseline visit and at week 4. A 30-minute dynamic
emission scan, consisting of six 5-minute frames was ac-
quired starting 30 minutes after the intravenous injection
of 5 mCi of 18F-FDG. Data was corrected for radiation-
attenuation and scatter using transmission scans or X-ray
computed tomography, and reconstructed using a stan-
dardized reconstruction algorithm.
Peripheral Src family kinase target engagement
Osteoclast function is known to be mediated through Src,
and therefore levels of cross-linked serum C-telopeptide
of type 1 collagen (sCTX) measurements have been used
in several studies as a surrogate marker of relevant bio-
logic function of AZD0530 [38,39]. sCTX levels were
measured at the baseline visit and at week 4 by enzyme-
linked immunosorbent assay (Immunodiagnostic Systems,
Boldon, UK) according to the manufacturer’s instructions.
Serum samples were stored at −80°C until analysis. All
samples collected from each individual subject were ana-
lyzed in the same batch by an investigator blinded to sub-
ject drug assignment.
Abl inhibition assay
An assay for plasma inhibitory activity against Abl kinase
followed previous procedures [40,41] by determining
the level of Abl-dependent phosphorylation of Stat5 in
leukemia cells incubated with plasma from patients. The
K-562 cells, a gift from Prof. Gary Kupfer, were main-
tained in RPMI 1640 supplemented with 10% fetal bovine
serum. To generate a dose–response curve for AZD0530
and STI-571, 1 × 105 K-562 cells were incubated in 100 μl
normal volunteer plasma in 96 well plates for 2 hours at
37°C in a humidified incubator with 5% CO2, with the ap-
propriate amount of drug added, diluted in equal volumesof DMSO. For experiments with patient samples, cells
were incubated in patient plasma samples, with the ex-
perimenter blinded to patient group. Cells were pelleted
by centrifuge, washed twice in 500 μl phosphate-buffered
saline, then lysed in 40 μl 2× Laemmli sample buffer
(LSB), boiled for 10 minutes and centrifuged. Lysates were
then loaded onto 8% SDS-PAGE gels, transferred to
nitrocellulose membranes, and immunoblotted using a
phospho-specific Stat5 antibody (Cell Signaling, Danvers,
MA, USA), and then stripped and re-probed using a Stat5
antibody (SantaCruz, Dallas, TX, USA). Immunoblots
were then quantified by densitometry, and the density
of each band normalized to a control sample treated with
volunteer plasma. Nonlinear regression was performed
to generate a dose–response curve of inhibition versus
AZD0530 and STI concentration.
Cerebrospinal fluid Alzheimer’s disease biomarkers
Levels of CSF Aβ40, Aβ42, Tau and P231-Tau were measured
using a Luminex assay system and a MagPix instrument,
according to the manufacturer’s instructions (Millipore,
Billerica, MA, USA). All assays were performed in a single
batch by an investigator blinded to subject assignments.
Rodent AZD0530 pharmacokinetics
To examine the correlation between plasma, CSF, and
brain levels of AZD0530 in a preclinical model, five mice
(C57B6/J) received a dose of 5 mg/kg per day adminis-
tered orally twice daily for 3 days. Trough plasma, CSF
and brain drug levels were measured by tandem reverse-
phase high-pressure liquid chromatography and mass
spectrometry. All animal work was approved by the Yale
Institutional Animal Care and Use Committee according
to established international guidelines.
Statistical analysis
At the completion of all three dose cohorts, the frequencies
of adverse events or laboratory abnormalities between the
participants who received each dose of AZD0530 (n = 6)
and the pooled placebo subjects (n = 6) were compared
using Fisher’s exact test. Changes in clinical outcomes
(MMSE, ADAS-cog, CDR-SOB, ADCS-ADL, NPI) were
examined using analysis of covariance or Kruskal-Wallis
H test (for non-normally distributed NPI data). Change in
18F-FDG PET cerebral metabolic rate for glucose (CMRgl)
from baseline to week 4 was analyzed using statistical para-
metric mapping sROI methods as previously published [42].
The effect of treatment assignment on change in CMRgl was
analyzed by four-group analysis of variance and t-test.
Results
Subject disposition
Thirty-one subjects were screened, with 24 meeting eli-
gibility criteria. Seven subjects were excluded as follows:
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roid stimulating hormone (1), thalamic infarct (1), and
abnormal liver function tests (1). Of the 24 subjects,
18/24 were randomized to one of three doses of AZD0350,
and the remaining six to placebo. One subject discontinued
treatment prematurely due to a serious adverse event, as
detailed below.
Baseline characteristics
Of the 24 subjects, 61% were female, with age ranging
from 55 to 86 years (mean ± SD, 73 ± 7) (Table 1); 96%
of subjects were Caucasian. Mean score on the MMSE
at baseline was 22.2 (±3). The treatment groups did not
differ significantly on any demographic or baseline clinical
efficacy variable. However, the 125-mg group was slightly
older and had a lower baseline MMSE score in compari-
son to other groups.
Safety and tolerability
In general, doses of AZD0530 ranging from 50 mg to
125 mg daily were reasonably well tolerated in patients
with mild-to-moderate AD. The number of participants
in each AZD0530 treatment group experiencing adverseTable 1 Subject characteristics and clinical efficacy assessmen
Variable Treatment group (dose of AZD0530)
Placebo (n = 6) 50 mg (n = 6)
Age 72.6 ± 9.5 72.6 ± 4.4
Sex 3 F, 3 M 5 F, 1 M
Education (years) 15.0 ± 2.8 15.3 ± 2.7
Weight (kg) 6.88 ± 12.1 69.7 ± 8.7
MMSE, baseline 23.0 ± 4.1 21.8 ± 3.3
MMSE, week 4 25.7 ± 3.3 25.3 ± 2.4
MMSE, change 2.7 ± 2.0 3.5 ± 1.9
ADAS-cog, baseline 16.7 ± 2.3 20.6 ± 6.7
ADAS-cog, week 4 15.2 ± 4.8 18.3 ± 4.5
ADAS-cog, change −1.6 ± 4.4 −2.3 ± 3.4
ADCS- ADL, baseline 63.5 ± 9.2 68.7 ± 6.8
ADCS- ADL, week 4 67.7 ± 10.6 66.5 ± 6.7
ADCS- ADL, change 4.2 ± 5.2 −2.2 ± 4.2
CDR-SOB, baseline 5.6 ± 2.2 5.3 ± 1.9
CDR-SOB, week 4 5.8 ± 2.4 5.0 ± 1.9
CDR-SOB, change 0.2 ± 0.4 −0.3 ± 0.6
NPI, baseline 9.5 ± 11.9 6.5 ± 6.1
NPI, week 4 4.0 ± 5.0 7.7 ± 9.1
NPI, change −5.5 ± 8.4 1.2 ± 5.1
Values are shown as mean ± standard deviation (apart from sex). F and P values are
¶Kruskal-Wallis H test. ‡Analysis of completer subjects only. Week 4 ADCS-ADL and
§Analysis of all randomized subjects, including AZD026 who discontinued study dru
1.9, F = 2.07, P = 0.140; ADAS-cog change = 1.3 ± 3.5, F = 1.05, P = 0.393; NPI chang
Assessment Scale – cognitive subscale; ADCS-ADL, Alzheimer’s Disease Cooperativ
Rating Scale – Sum of Boxes; F, female; M, male; MMSE, Mini Mental Status Examievents is presented in Table 2. Treatment-emergent ad-
verse events were reported for three participants in the
placebo group, and four, five, and four participants in
the 50-mg, 100-mg, and 125-mg groups, respectively. All
adverse events were of mild or moderate severity. Two
participants in the 125-mg dose group had moderately
severe events, compared to one each for the 100-mg and
placebo groups. The most common individual adverse
events were diarrhea, headache, fatigue, and nausea, which
tended to occur more frequently with higher doses of
AZD0530 but were numerically most frequent in the
placebo group. The effect of treatment group was not
statistically significant for any adverse event.
The only serious adverse event (SAE) occurred in a
participant who was receiving 125 mg AZD0530. After
9 days of treatment, the subject was hospitalized with
4 days of fatigue, anorexia, and myalgias, and 1 day of
shortness of breath. A low-grade fever with a maximum
temperature of 100.1 °F was recorded after hospital ad-
mission. The diagnosis was felt to be most consistent
with congestive heart failure, precipitated by pneumonia;
however, a drug-induced pneumonitis could not be en-
tirely ruled out. An infectious organism was not isolated.ts
100 mg (n = 6) 125 mg (n = 6) F P
71.5 ± 4.9 4.6 ± 7.9 0.57 † 0.19
2 F, 4 M 3 F, 3 M
14.3 ± 2.3 16.8 ± 3.4 0.84 † 0.49
79.6 ± 17.9 65.4 ± 10.4 1.37 † 0.28
22.2 ± 4.6 20.2 ± 2.3 0.63 † 0.60
22.7 ± 4.0 22.5 ± 3.3
0.5 ± 3.4 2.3 ± 2.1 2.15 § 0.13
23.8 ± 4.5 21.6 ± 7.1 1.73 † 0.19
22.3 ± 8.1 23.0 ± 4.4
−1.4 ± 5.4 1.4 ± 3.2 1.31 § 0.30
67.2 ± 6.4 64.8 ± 3.1 0.67 † 0.58
68.2 ± 7.6 66.4 ± 4.3
1.0 ± 2.0 1.6 ± 3.4 2.27 ‡ 0.12
4.8 ± 1.2 5.1 ± 1.8 0.22 † 0.88
4.8 ± 1.2 5.6 ± 1.9
0.0 ± 0.0 0.5 ± 0.4 2.60 ‡ 0.08
3.7 ± 4.3 13.2 ± 10.1 ¶ 0.37
2.5 ± 3.5 18.0 ± 8.9
−1.2 ± 4.8 4.8 ± 7.6 ¶ 0.09
for analysis of covariance, controlling for baseline score. †Analysis of variance.
CDR-SOB invalid for subject AZD026, who was residing in skilled nursing facility.
g after 9 days; excluding this subject, MMSE change in 125-mg group = 2.8 ±
e = 1.8 ± 1.9, P = 0.169, Kruskal-Wallis H test. ADAS-cog, Alzheimer’s Disease
e Study – Activities of Daily Living Inventory; CDR-SOB, Clinical Dementia
nation; NPI, Neuropsychiatric Inventory.
Table 2 Number of participants in each AZD0530 treatment group experiencing an adverse event
Treatment group (AZD0539 dose; n = 6 per group)
Adverse event Placebo 50 mg 100 mg 125 mg Total
Any adverse event* 3 4 5 4 16
Diarrhea 2 0 1 2 5
Headache 2 1 1 1 5
Fatigue 1 0 0 2 3
Nausea 2 0 0 1 3
Pneumonia, atypical/bronchitis 0 0 0 1 1
Congestive heart failure 0 0 0 1 1
Renal insufficiency, worsened 0 0 0 1 1
Elevated serum creatinine 0 0 0 1 1
Cough, worsened 0 0 0 1 1
Postnasal drip 0 0 0 1 1
Pulmonary hypertension 0 0 0 1 1
Anorexia 0 0 0 1 1
Tinnitus 0 0 0 1 1
Myalgias 0 0 0 1 1
Squamous cell carcinoma 0 0 1 0 1
Basal cell carcinoma 0 0 1 0 1
Wrist pain 0 0 1 0 1
Noncardiac chest pain 0 0 1 0 1
Upper respiratory infection 0 1 0 0 1
Flu-like symptoms 0 1 0 0 1
Lightheadedness 0 1 0 0 1
Vomiting 1 0 0 0 1
*Includes participants who reported at least one adverse event. The effect of treatment group is not significant for any adverse event or individual adverse events
(Fisher’s exact test, P > 0.05).
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treated with diuretics and antibiotics, gradually making a
full recovery to baseline health. The overall conclusion
was that this event was possibly related to the study drug.
Apart from this SAE, no other participant prematurely
discontinued study medication.
Two subjects receiving AZD0530 125 mg daily, one of
which experienced the SAE described, had significant
laboratory abnormalities that subsequently reversed:
elevated serum creatinine, considered possibly related
to study medication, and worsened renal insufficiency,
unlikely related to study medication. There were no
significant hematological changes, including platelet counts
and absolute neutrophil counts. No significant changes in
measures of vital signs or electrocardiogram readings were
seen across AZD0530 doses.
AZD0530 drug levels in human cerebrospinal fluid at
different doses
We compared the CSF drug levels across the AZD0530
dosage groups. There was variability within any onegroup, but dose dependency was established (Figure 1A).
The increase in CSF drug level was greater than linear,
with a three-fold increase from 50 to 100 mg and a two-
fold increase from 100 to 125 mg, most consistent with
an exponential relationship. The trough CSF drug level
at 50 mg was 0.5 to 1.2 ng/ml (0.9 to 2.2 nM). The
trough CSF drug level at 100 mg was 1.1 to 4.5 ng/ml
(2.1 to 8.3 nM). The trough CSF drug level at 125 mg
was 1.4 to 7.6 ng/ml (2.5 to 14.0 nM). Using the ratio of
CSF:brain in mice measured to be 1:3, the estimated
human brain concentrations at 50 mg = 3 to 7 nM, at
100 mg = 7 to 27 nM and at 125 mg = 8 to 46 nM. The
Fyn Ki for AZD0530 is 5 to 10 nM. Analysis of the pre-
clinical efficacy of AZD0530 in a mouse model of AD is
reported elsewhere [43]; 5 mg/kg per day administered
for 4 to 6 weeks reverses memory impairments in this
model, corresponding to trough CSF levels in humans
seen at doses of 100 to 125 mg/day (Figure 1A).
We collected both CSF and plasma for AZD0530 drug
levels at the week-4 endpoint. There was a close correl-
ation between free AZD0530 drug levels in plasma and










































Figure 1 AZD0530 in human cerebrospinal fluid at different doses. (A) Each point represents fasting trough cerebrospinal fluid (CSF) AZD0530
level from a different human subject for the left three columns. The mouse trough CSF values are derived from brain levels at the 5 mg/kg per day
dose that rescued memory deficits [43]. **P < 0.001, one-way analysis of variance with Tukey post-hoc comparisons. (B) Relationship between CSF and
plasma AZD0530 levels. Each point is from a different individual, and different dose groups are illustrated with different colors. There is a tight
correlation of plasma and CSF level as indicated (R2 = 0.97, Pearson correlation coefficient). Bars represent mean ± standard error of the mean.
n.s, Not significant.
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All subjects underwent standard clinical efficacy assess-
ments at baseline and at the week-4 endpoint (Table 1).
There was a tendency for MMSE scores to improve over
time, which may have been due to practice effects as the
MMSE was also administered at weekly visits as a safety
measure. No statistically significant effect of treatment
was observed on any of clinical efficacy assessment mea-
sures, including ADAS-cog, ADCS-ADL, CDR-SOB, and
NPI. The lack of a treatment effect was not surprising
given the small sample sizes and the short duration of
treatment, and with an investigational therapy that is being
developed primarily for longer-term disease- modifying








Figure 2 AZD0530 peripheral target engagement. Four-week
treatment with 100 mg and 125 mg AZD0530 reduces serum cross-
linked C-telopeptide of type 1 collagen (sCTX), a marker of osteoclast
activity. Compared to placebo, mean difference in the change in sCTX
from baseline for 50 mg was 51% (95% confidence interval, −22.0 to
124.3), for 100 mg 85% (95% confidence interval, 8.2 to −161.6), and for
125 mg 83% (95% confidence interval, 6.2 to 159.6). **P< 0.05, analysis
of variance with Dunnet’s multiple comparisons test. n.s., Not significant.18F-FDG PET measurements
The effect of treatment with AZD0530 on 1-month re-
ductions in CMRgl using statistical parametric mapping
sROI was assessed using 18F-FDG PET imaging. Of the
24 subjects, 22 underwent measurements of CMRgl at
baseline, and after 4 weeks on study drug or placebo.
There was no effect of treatment group on change in a
prespecified sROI consisting of voxels associated with pref-
erential 12-month CMRgl declines in previously studied
patients with the clinical diagnosis of mild-to-moderate
AD dementia (F = 0.37, P = 0.78, df = 3.17, analysis of vari-
ance). A post-hoc comparison of change in CMRgl for clin-
ically relevant doses of AZD0530 (100 or 125 mg daily)
versus placebo revealed no significant differences in the
rate of decline for CMRgl between AZD0530 100 to125 mg daily (0.87 ± 1.86%) versus placebo (1.26 ± 2.24%;
P = 0.71).
Peripheral target engagement
To provide a readily accessible marker of peripheral Src
family kinase target inhibition, we assayed sCTX. This
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a cell in which Src plays an important regulatory role.
AZD0530 is reported to decrease sCTX in humans in a
dose-dependent fashion [38]. Our results confirm Src per-
ipheral target engagement, with a decrease in serum sCTX
after 4 weeks of daily 100- to 125-mg AZD0530 adminis-
tration (Figure 2).
AZD0530 does not inhibit Abl kinase at doses up to 125 mg
AZD0530 has highest activity against Src family kinases,
with little or no potency against a panel of other kinases.
The only other detectable activity is against Abl kinase,
with a Ki approximately 15-fold higher [28,44]. Therefore,
we measured the activity of plasma inhibitory activity of
AZD0530 against Abl kinase, by monitoring the level of
Stat5 phosphorylation as a substrate of Abl in leukemia
cells as described [40,41]. While the Abl kinase inhibi-
tor STI-571 inhibits Abl to Stat5 signaling with a half
maximal inhibitory concentration (IC50) of 1.6 nM in
cells incubated with plasma, the IC50 for AZD0530 is
nearly 100-fold higher, at 156 nM (Figure 3A,B). Plasma
samples from subjects treated with 0, 50, 100 and 125 mg
were incubated with the leukemia cells in vitro, and
pStat5 measured as a read out of Abl kinase activityFigure 3 Plasma from AZD0530-treated subjects does not inhibit Abl
cells incubated with the indicated concentrations of AZD0530 or STI-571 is
microdensitometry and a half maximal inhibitory concentration (IC50) dete
was detected by pStat5 level in K-562 cells incubated with plasma from su
Abl inhibitory activity determined by pStat5 level was measured in all subject
difference between groups was observed (n.s.).(Figure 3C,D). No significant inhibition of Abl kinase
was observed. Thus, at these doses of AZD0530, kinase in-
hibition is specific for the Src family (Figure 2), without
significant alterations in Abl kinase activity (Figure 3D).Cerebrospinal fluid biomarkers
Levels of total Aβ40, Aβ42, Tau, and p-Tau were assessed
in CSF samples from all subjects in the study after 4 weeks
of study medication. Although we did not obtain CSF at
baseline to analyze drug effects on CSF biomarkers, we
found no difference in levels of any AD biomarker at
the 4-week endpoint between subjects treated with 100
to 125 mg AZD0530 and placebo (for Aβ40: placebo,
4,876 pg/ml (±789 pg/ml); AZD0530 100 mg, 3,963 pg/ml
(±624 pg/ml); AZD0530 125 mg, 4,501 pg/ml (±311 pg/
ml); for Aβ42: placebo, 601 pg/ml (±81 pg/ml); AZD0530
100 mg, 523 pg/ml (±48 pg/ml); AZD0530 125 mg,
553 pg/ml (±34 pg/ml); for total tau: placebo, 0.53 ng/ml
(±0.17 ng/ml); AZD0530 100 mg, 0.57 ng/ml (±0.20 ng/
ml); AZD0530 125 mg, 0.57 ng/ml (±0.14 ng/ml); for p
(T231)-Tau: placebo, 5.33 nM (±2.29 nM); AZD0530
100 mg, 5.88 nM (±1.89 nM); AZD0530 125 mg, 5.21 nM
(±1.80 nM)).signaling to Stat5. (A) The level of pStat5 and total Stat5 in K-562
shown. (B) The pStat5 level from experiments in (A) was measured by
rmined for each compound. (C) The plasma inhibitory activity for Abl
bjects treated with the indicated doses of AZD0530. (D) The plasma
s, and is plotted as mean ± standard error of the mean. No significant
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Preclinical studies in both rodent models and patients
with AD indicate that Fyn may be a promising target for
novel therapeutic intervention [23]. Here, we report a
Phase Ib study to explore the use of a Fyn-specific Src
family kinase inhibitor for the treatment of patients with
AD. Our study shows that 100 mg and 125 mg doses
achieved CSF levels corresponding to brain levels that
rescued memory deficits in transgenic AD mouse models.
A therapeutic benefit was not expected after a 1-month
treatment period, and no treatment effect was observed
across doses of AZD0530 on measures of cognitive and
neuropsychiatric function, activities of daily living, or cere-
bral glucose metabolism.
Some safety and tolerability issues may emerge, particu-
larly at the 125 mg dose. However, the tight correlation
between plasma and CSF levels of AZD0530 will enable
individualized dosing within the 100 to 125 mg range,
based on early plasma level monitoring. Individualized
dosing may maximize the number of subjects who
reach the target CSF drug concentration of 5 nM, while
minimizing those who encounter safety and tolerability
problems. Fyn regulates a diverse set of cellular func-
tions, including cell proliferation, migration, and differ-
entiation, synaptic function, CNS myelination, T cell
signaling, and platelet function [23], emphasizing not
only the importance of careful safety and tolerability
monitoring in larger clinical trials, but also the goal of
normalizing aberrant Fyn activity in AD, without signifi-
cantly altering its physiologic functions. Previous experi-
ence with AZD0530 has indicated a possible, but rare,
relationship with interstitial lung disease in patients with
advanced solid tumors [33]. The single SAE in this study
involved a case of congestive heart failure and pneumonia,
for which a drug-induced pneumonitis could not be en-
tirely ruled out. Although no conclusive link has been
established between AZD0530 and drug-induced pneu-
monitis, future trials of AZD0530 for AD should continue
to monitor this possibility with thoracic high-resolution
computed tomography for any unexplained pulmonary
symptoms. We recognize the limitations of our results due
to the relatively small sample size and the short duration of
treatment. These limitations will be addressed by a larger
Phase IIa clinical trial of AZD0530 in AD (NCT02167256).
Masitinib, a tyrosine kinase inhibitor selective for c-Kit,
platelet-derived growth factor, Lyn, and to a lesser degree
Fyn, was recently used in a 24-week, Phase II dose-ranging
trial in France, involving 34 patients with mild-to-moderate
AD [45]. The trial showed reasonable tolerability, and drug
treatment was associated with improvements in cognition
and daily function at 12 and 24 weeks. A large international
Phase III trial was launched in 2013 to evaluate the efficacy
and safety of two doses of masitinib compared to placebo
(NCT01872598). The Phase II data provide further clinicalsupport for tyrosine kinase inhibition as a treatment strat-
egy in AD.
Conclusions
The current Phase Ib trial demonstrates that AZD0530
is generally safe and well tolerated in patients with AD,
with oral dosing yielding excellent CNS drug concentra-
tion. Together with our preclinical data, the Phase Ib
study results support the dosing regimen for a larger on-
going Phase IIa trial in AD of 100 to 125 mg AZD0530
daily (NCT02167256).
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